General News Oxurion NV – Publication in ‘Progress in Retinal and Eye Research’ highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD EN April 7, 2021
General News Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group EN April 6, 2021
General News Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN January 20, 2021
